Journal of Pathology and Translational Medicine

Case Study

Follicular Proliferative Lesion Arising in Struma Ovarii: Min Jee Park, Min A Kim, Mi Kyung Shin, Hye Sook Min; J Pathol Transl Med. 2015;49(3):262-266. Published online May 15, 2015; DOI: https://doi.org/10.4132/jptm.2015.03.26

8,158 View
129 Download
4 Web of Science
6 Crossref

Malignant struma ovarii is extremely rare and difficult to diagnose histologically, particularly in cases of follicular carcinoma. This case study is intended to describe three cases of follicular proliferative lesion arising in struma ovarii that we experienced. The first case was clearly malignant given the clinical picture of multiple recurrences, but there was little histological evidence of malignancy. Our second case featured architectural and cellular atypia and necrosis and was diagnosed as malignant despite the absence of vascular and stromal invasion. Our third case exhibit-ed solid microfollicular proliferation without any definite evidence of malignancy (even the molecular data was negative); however, we could not completely exclude malignant potential after conducting a literature review. In cases such as our third case, it has been previously suggested that a diagnostic term recognizing the low-grade malignant potential, such as “proliferative stromal ovarii” or “follicular proliferative lesion arising in the stromal ovarii” would be appropriate.

Citations

Citations to this article as recorded by

Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii
Sophie Neyrand, Alexis Trecourt, Jonathan Lopez, Pierre Alexandre Just, Françoise Descotes, Françoise Borson‐Chazot, Isabelle Ray‐Coquard, Myriam Decaussin‐Petrucci, Mojgan Devouassoux‐Shisheboran
Histopathology.2024; 84(2): 291. CrossRef
Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations
Roberta Poli, Maria Scatolini, Enrico Grosso, Francesca Maletta, Marco Gallo, Daniele Liscia, Anna Nelva, Flora Cesario, Giuseppe Forte, Jasna Metovic, Marco Volante, Emanuela Arvat, Mauro Papotti
Endocrine.2021; 71(1): 216. CrossRef
Proliferative struma ovarii: A rare case report
Shankhanila Mazumdar, GaganKumar Rangari, Neeraj Dhameja, NishaRani Agrawal
International Journal of Clinicopathological Correlation.2021; 5(2): 85. CrossRef
Malignant struma ovarii presenting with follicular carcinoma: A case report with molecular analysis
Takafumi Tsukada, Hiroshi Yoshida, Mitsuya Ishikawa, Yuka Asami, Kouya Shiraishi, Tomoyasu Kato
Gynecologic Oncology Reports.2019; 30: 100498. CrossRef
A Rare Case: Struma Ovarii in a 14-Year-Old Girl
Elif Iltar, Isin Ureyen, Tayfun Toptas, Melike Savas, Sema Çekiç, Aysel Uysal
Journal of Adolescent and Young Adult Oncology.2018; 7(1): 134. CrossRef
Proliferative Highly Differentiated Follicular Carcinoma Of Ovarian Origin (Hdfco) Presenting Long After Bilateral Oophorectomy
Natalie M. Liu, Neda Moatamed, Racquel S. Bueno, Wendy L. Sacks
AACE Clinical Case Reports.2017; 3(3): e264. CrossRef

Original Articles

The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma: Min Hye Jang, Kyeong Cheon Jung, Hye Sook Min; J Pathol Transl Med. 2015;49(2):112-117. Published online March 12, 2015; DOI: https://doi.org/10.4132/jptm.2015.01.31

7,851 View
70 Download
11 Web of Science
12 Crossref

Abstract PDF

Background
Follicular thyroid carcinoma (FTC) is the second most common thyroid malignancy and its differential diagnosis includes follicular adenoma (FA) and adenomatous goiter (AG). Several ancillary markers have been suggested to aid in the diagnosis of FTC, but the successful use of these methods still needs to be validated. Methods: In the present study, we verified the immunoexpression of HMGA2, CEACAM6, survivin, and SFN/14-3-3 δ in lesions including 41 AGs, 72 FAs, and 79 FTCs. We evaluated their diagnostic usefulness, combined with galectin 3, Hector Battifora mesothelial 1 (HBME1), cytokeratin 19, and cyclin D1, in diagnosing FTC. Results: The expressions of HBME1 (65.8%) and HMGA2 (55.7%) were significantly higher in FTCs than in FAs and AGs (p<.001 and p=.005, respectively). HBME1 was the only marker that was more frequently expressed in FTCs than in FAs (p=.021) and it was more frequently expressed in follicular neoplasms than in AGs (p<.001). Among the novel markers, the combination of HMGA2 and HBME1 showed the highest sensitivity (72.2%) and specificity (76.1%) for diagnosing FTC. CEACAM6, survivin, and SFN/14-3-3 δ were barely expressed in most cases. Conclusions: Our present results show that only HMGA2 can be beneficial in differentiating FTC using the novel markers.

Citations

Citations to this article as recorded by

HMGA2 promotes nasopharyngeal carcinoma progression and is associated with tumor resistance and poor prognosis
Xinting Ouyang, Kangxin Li, Jiaqi Wang, Weijian Zhu, Qiang Yi, Jinghua Zhong
Frontiers in Oncology.2024;[Epub] CrossRef
miR‐98‐5p promotes apoptosis and inhibits migration and cell growth in papillary thyroid carcinoma through Bax/Caspase‐3 by HMGA2
Kai Qiu, QingJi Xie, Shan Jiang, Ting Lin
Journal of Clinical Laboratory Analysis.2020;[Epub] CrossRef
High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis
Yen Thi-Hai Pham, Ovie Utuama, Claire E. Thomas, Jong A. Park, Carlo La Vecchia, Harvey A. Risch, Chi Thi-Du Tran, Thanh V. Le, Paolo Boffetta, Leon Raskin, Hung N. Luu
European Journal of Cancer Prevention.2020; 29(6): 565. CrossRef
Diagnostic performance of HMGA2 gene expression for differentiation of malignant thyroid nodules: A systematic review and meta‐analysis
Bo Hyun Kim, Seong Jang Kim, Mijin Kim, Sang‐Woo Lee, Shin Young Jeong, Kyoungjune Pak, Keunyoung Kim, In Joo Kim
Clinical Endocrinology.2018; 89(6): 856. CrossRef
Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution
Geneviève Dom, Sandra Frank, Sebastien Floor, Pashalina Kehagias, Frederick Libert, Catherine Hoang, Guy Andry, Alex Spinette, Ligia Craciun, Nicolas de Saint Aubin, Christophe Tresallet, Frederique Tissier, Frederique Savagner, Samira Majjaj, Ilse Gutier
Oncotarget.2018; 9(12): 10343. CrossRef
APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions
Esmeralda Castelblanco, Carles Zafon, Javier Maravall, Pilar Gallel, Montserrat Martinez, Ismael Capel, Maria Rosa Bella, Irene Halperin, Jordi Temprana, Carmela Iglesias, Manel Puig-Domingo, Mercedes Robledo, Xavier Matias-Guiu, Didac Mauricio
Thyroid.2017; 27(1): 59. CrossRef
Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma
Yourha Kim, Min-Hee Kim, Sora Jeon, Jeeyoon Kim, Chankyung Kim, Ja Seong Bae, Chan Kwon Jung, Yves St-Pierre
PLOS ONE.2017; 12(3): e0174737. CrossRef
Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level
Joanna Waligórska-Stachura, Nadia Sawicka-Gutaj, Maciej Zabel, Mirosław Andrusiewicz, Paweł Gut, Agata Czarnywojtek, Marek Ruchała
Oncology Letters.2017; 13(4): 2437. CrossRef
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma
Adelaide Greco, Sandra Albanese, Luigi Auletta, Peppino Mirabelli, Antonella Zannetti, Crescenzo D'Alterio, Gennaro Di Maro, Francesca Maria Orlandella, Giuliana Salvatore, Andrea Soricelli, Marco Salvatore
Thyroid.2016; 26(4): 552. CrossRef
The study of galectin-3, Ki-67, ubiquitin, HMGA-2 by polymerase chain reaction in real time (RT-PCR) in the puncture specimens of nodular goiter
Irina S. Berjozkina, Tat'jana V. Saprina, Anastasija P. Zima, Anna V. Isaeva, Venera N. Latipova, Marat R. Muhamedov, Leonid R. Bazilevich, Oleg S. Popov, Dar'ja A. Skuratovskaja, Kristina A. Jurova, Larisa C. Litvinova
Clinical and experimental thyroidology.2016; 12(2): 19. CrossRef
High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients
Zhuoxing Liu, Kunpeng Wu, Zhixiong Yang, Aibing Wu
Molecular and Cellular Biochemistry.2015; 409(1-2): 155. CrossRef
Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature
Duško Dunđerović, Jasmina Marković Lipkovski, Ivan Boričic, Ivan Soldatović, Vesna Božic, Dubravka Cvejić, Svetislav Tatić
Diagnostic Pathology.2015;[Epub] CrossRef

Expressions of Id-1 and Id-2 in Hyperplastic Thyroid Tissue and Thyroid Carcinoma.: Young A Kim, Young Joo Park, Do Joon Park, Seong Hoe Park, Ji Eun Kim; Korean J Pathol. 2006;40(1):60-65.

5,198 View
16 Download

Abstract PDF: BACKGROUND
Id proteins are a family of helix-loop-helix proteins and are regarded to be negative regulators of cell differentiation. In general, Id-1 and Id-2 expressions are upregulated during tumor development and progression in a variety of neoplasms, and these expressions may be associated with aggressive tumor behavior. However, little is known about the roles of Id-1 and Id-2 in thyroid neoplasms.
METHODS
The expressions of Id-1 and Id-2 were assessed immunohistochemically in 310 normal, hyperplastic, and neoplastic thyroid tissues using tissue microarrays.
RESULTS
Normal thyroid tissues rarely expressed Id-1 or Id-2. Moreover, whilst Id-1 expression was more elevated in malignant thyroid tissue than in hyperplastic thyroid tissue, Id-2 expression was more variable. No significant differences were observed between histologic subtypes of thyroid carcinomas with respect to Id-1 or Id-2 expression. Follicular adenomas showed higher expressions of Id-1 and Id-2 than thyroid carcinomas. No significant association was found between clinicopathological parameters and Id-1 expression, though Id-2 expression was significantly reduced in metastatic, stage IV tumors.
CONCLUSION
The expressions of Id-1 and Id-2 were elevated in hyperplastic and neoplastic thyroid tissues. However, neither appears suitable as a marker of malignancy or an aggressive phenotype, although Id-2 expression in advanced thyroid carcinomas may reflect a favorable prognosis.

First
Prev
Page of 1
Next
Last

Search